Cargando…

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

BACKGROUND: Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) are the three components of the once-daily, single tablet regimen (Atripla) for treatment of HIV-1 infection. Previous cell culture studies have demonstrated that the double combination of tenofovir (TFV), the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Joy Y, Ly, John K, Myrick, Florence, Goodman, Derrick, White, Kirsten L, Svarovskaia, Evguenia S, Borroto-Esoda, Katyna, Miller, Michael D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693498/ https://www.ncbi.nlm.nih.gov/pubmed/19439089 http://dx.doi.org/10.1186/1742-4690-6-44

Ejemplares similares

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals
por: Moyle, Graeme J., et al.
Publicado: (2015)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India
por: Pujari, Sanjay, et al.
Publicado: (2008)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
por: Peng, Yongquan, et al.
Publicado: (2023)

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
por: Barat, Stephen, et al.
Publicado: (2017)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
por: Jing, Cao, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
por: Xia, Huan, et al.
Publicado: (2021)

Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
por: Stirrup, Oliver T, et al.
Publicado: (2019)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017)

1591 Hepatitis B outcome in coinfected HIV-HBV individuals in the tenofovir/emtricitabine era
por: Nguyen, Divien, et al.
Publicado: (2014)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2018)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)
por: Huang, David, et al.
Publicado: (2021)

Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats
por: Everson, Frans, et al.
Publicado: (2018)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019)

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017)

1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Huang, David, et al.
Publicado: (2021)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2 )vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
por: Focà, Emanuele, et al.
Publicado: (2012)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
por: Chen, Xinhui, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e4mu01ifif845nicstnck1j1tc